Sudden unexpected death is a terrifying consequence faced by people living with uncontrolled tonic-clonic seizures (TCSs), so ...

As clinical research sites come under growing operational pressure, sponsors and CROs are being challenged to rethink how studies are designed and supported. Protocols are becoming more complex.

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, can achieve a functional cure in 19% of patients, ...

The FDA has started a priority review of Sanofi's Gaucher disease therapy venglustat, a potentially first-in-class therapy, ...

Big pharma group GSK has been ruling the market for shingles vaccines for many years, but little Dynavax Technologies has aspirations to knock off its crown. The Emeryville, California-based biotech ...

The FDA has approved AbbVie's Decnupaz, a treatment for rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN) that was one of the assets in its $10.1 billion takeover of ImmunoGen in ...

If a patient reaches a healthy weight and improves their metabolic profile, the idea of remaining on therapy indefinitely ...

Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in Europe for ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...

Non-profit research organisation Biohub has released what it claims is an AI-powered "world model" of protein biology that ...

After its advisory committee voted against AstraZeneca's camizestrant as a treatment for breast cancer in April, the FDA has ...

Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with ...